Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector

Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector John R. Kouvaris, Vassilis E. Kouloulias, Lampros J. Vlahos Oncologist 2007; 12: 738-747 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in symptom management and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Select appropriate multidisciplinary treatment regimens and cytoprotection for clinical trials for patients with head and neck cancer. Identify radiation toxicity for the head and neck, lung, and pelvic irradiated areas. Describe the cytoprotective effect of amifostine against radiation toxicity. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jun. 29, 2007 Most Recent Review: Jun. 29, 2007* Most Recent Update: Jun. 29, 2007 Date Credit Expires: Jun. 29, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course